Lumosa Therapeutics Co., Ltd.
Research Lumosa Therapeutics Co., Ltd. (6535.TWO) on Bullrun: market cap TWD 12.71B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6535.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 12.71B
- Financial periodQ2 2026
- RevenueTWD 5.13M
- Net income-TWD 161.93M
- Free cash flow-TWD 116.40M
- Gross margin31.5%
Valuation Snapshot
latest market cap is TWD 12.71B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 12.71B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Lumosa Therapeutics Co., Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders;
ETFs that hold Lumosa Therapeutics Co., Ltd.
US-listed ETFs
Lumosa Therapeutics Co., Ltd. is held by 10 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Core MSCI Emerging Markets ETF (IEMG) | <0.01% | 0.09% |
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Small-Cap Index Fund ETF Shares (VSS) | 0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
| State Street SPDR Portfolio MSCI Global Stock Market ETF (SPGM) | <0.01% | 0.09% |
| iShares MSCI Emerging Markets Small-Cap ETF (EEMS) | 0.02% | 0.72% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lumosa Therapeutics Co., Ltd.'s market cap?
Lumosa Therapeutics Co., Ltd.'s market capitalization is TWD 12.71B.
What does Lumosa Therapeutics Co., Ltd. do?
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke; LT6001, which is in pre-clinical trials for the treatment of neurological disorders; and CS028, which is in the pre-clinical stage for the treatment of solid tumors.